Wilson Sonsini Advises Enable Injections on $215 Million Series C

On January 27, 2022,  Enable Injections, Inc., a company developing and manufacturing the enFuse platform of investigational wearable drug delivery systems, announced $215 million in Series C financing. Magnetar Capital led the financing along with new institutional investments from GCM Grosvenor, Squarepoint Capital, Woody Creek Capital Partners, and other investors. Enable received significant continued support from existing investors including Cincinnati Children's Hospital Medical Center, CincyTech, Cintrifuse, and Ohio Innovation Fund. Wilson Sonsini Goodrich & Rosati advised Enable Injections on the transaction.

Enable Injections' enFuse is an innovative drug delivery technology designed to subcutaneously deliver large volumes of up to 50mL for a wide range of therapies and diseases, and to provide patients and providers a safe, convenient, and cost-effective alternative to IV administration. With improved flexibility for patients and providers, enFuse is designed to enable an increase in healthcare provider efficiencies, minimize patient exposure in the clinic, and reduce healthcare costs, with the aim of benefiting patients and healthcare providers worldwide. According to Mike Hooven, president and CEO of Enable Injections, the funding from Magnetar will help enFuse continue to redefine intravenous drug delivery by meaningfully scaling the company’s development and commercialization efforts. This will help Enable reach even more patients who depend on intravenous medications.

The Wilson Sonsini team that advised Enable Injections on the transaction includes Elton Satusky, Andy Hirsch, Erik Franks, Jesse Schumaker, Alex Weber, Victor MacDiarmid, and Jason Koo.

For more information, please see Enable’s press release.